IJPRS

Home Abstract

Review on Sitagliptin


Received On: 23/05/2014
Accepted On: 01/06/2014


Author(s)

Ravinandan, A. P., Basavanagowda, G. M., Jimmy, O. D., Kumar, S. L.


Author's Affiliation


Abstract

Sitagliptin is also known as Januvia which contains the active substance sitagliptin which is a member of a class of medicines called as dipeptidyl-peptidase-4 inhibitors (DPP-4 ) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus. Sitagliptin is the first dipeptidyl-peptidase-4 inhibitor which is used in the treatment of diabetes mellitus. It is very useful in improving β-cell function and reducing sugar level in the blood and also used in the special circumstances like chronic kidney diseases with appropriate dose adjustment. It is one of the most effective dipeptidyl-peptidase-4 inhibitor involved in reducing glycosylated hemoglobin (HbA1c), fasting as well as postprandial blood sugar levels when used as monotherapy or in combination with other oral hypoglycemic agents. In this review article we have summarized all the previous studies relevant to sitagliptin use in the clinical practice.


Keywords

Sitagliptin, Dipeptidyl-Peptidase-4 Inhibitors, Type 2 Diabetes Mellitus, Glycosylated Hemoglobin

Cite This Article

Ravinandan, A. P., Basavanagowda, G. M., Jimmy, O. D., & Kumar, S. L. (2014). Review on Sitagliptin. International Journal for Pharmaceutical Research Scholars (IJPRS), 3(2), 577-581.


Recent Articles

Get FREE Updates for Upcoming
Pharma News, Jobs & Conferences

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

IJPRS will use the information you provide on this form to be in touch with you and to provide updates and marketing.